/
Musculoskeletal
Myelopathy
0
Pipeline Programs↗
4
Active Trials↗
3
Companies Involved↗
Myelopathy is an early-stage landscape with 0 programs across 3 companies. The most active players are ESTEVE Pharmaceuticals SAS.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
18
clinical trials
Completed8 · 44%
Unknown status3 · 17%
Recruiting3 · 17%
Terminated2 · 11%
Withdrawn1 · 6%
Not yet recruiting1 · 6%
Clinical Trials
Trial Activity
18 trials
Regeneration in Cervical Degenerative Myelopathy
Recruiting·—·Phase 3·NCT04631471·400 enrolled
Treatment of AIDS Vacuolar Myelopathy With Methionine
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00032695·56 enrolled
A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
Terminated·—·Phase 4·NCT01561755·12 enrolled
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
Withdrawn·—·Phase 4·NCT01992562
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)